Grants and Contributions:

Title:

Infrastructure capacity modification to support cGMP-compliant manufacture of lentiviral vectors at CETC

Agreement Number:

972253

Agreement Value:

$1,000,000.00

Agreement Date:

Apr 1, 2021 - Mar 31, 2025

Description:

This Project aims at establishing a current Good Manufacturing Practices (cGMP)-compliant platform to manufacture clinical grade lentiviral vectors (including production, purification and quality control) at the Centre of Excellence for Cellular Therapy (CETC) of Hôpital Maisonneuve-Rosemont. It builds on the capacity of the CETC, the only fully operational cGMP-compliant cell therapy facility in Canada, to generate viral vectors of clinical and commercial grade at the 50L scale. The Project involves: 1) generating the documentation during its purchase, 2) its qualification, 3) validation of the manufacture process, and 4) training and knowledge dissemination. At the end of the Project, a fully functional cGMP- compliant viral vector production manufacturing platform will be available in Canada to ensure accessibility of affordable cell and gene therapies for Canadians.

Organization:

National Research Council Canada

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:

Montreal, Quebec, CA H1T 2M4

Reference Number:

172-2021-2022-Q1-972253

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

787733690

Recipient Type:

Not-for-profit organization or charity

Additional Information:

This agreement has been amended 2 time(s). The end date of this agreements has been modified by 639 days.

Amendment Date

May 10, 2023

Recipient's Legal Name:

Centre for Commercialization of Cancer Immunotherapy

Federal Riding Name:

Hochelaga

Federal Riding Number:

24028

Program:

Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:

541710

Amendments:

See Amendments